CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., today announced encouraging preclinical data that show the potential of AV-412, a novel next generation oral tyrosine kinase inhibitor, as a therapeutic agent for the treatment of drug-resistant cancers expressing EGFR and ErbB2 mutations, such as non-small cell lung cancer and breast cancer. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Tanabe Pharma Corporation in 2006.
